Marker Therapeutics, Inc. (MRKR)
NASDAQ: MRKR · IEX Real-Time Price · USD
4.110
+0.060 (1.48%)
At close: May 1, 2024, 4:00 PM
4.100
-0.010 (-0.24%)
After-hours: May 1, 2024, 4:00 PM EDT
Marker Therapeutics Revenue
In the year 2023, Marker Therapeutics had annual revenue of $3.31M, a decrease of -5.76%. Revenue in the quarter ending December 31, 2023 was $1.06M with 39.17% year-over-year growth.
Revenue (ttm)
$3.31M
Revenue Growth
-5.76%
P/S Ratio
11.05
Revenue / Employee
$413,892
Employees
8
Market Cap
36.59M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 3.31M | -202.41K | -5.76% |
Dec 31, 2022 | 3.51M | 2.27M | 182.96% |
Dec 31, 2021 | 1.24M | 774.93K | 166.01% |
Dec 31, 2020 | 466.79K | 253.59K | 118.95% |
Dec 31, 2019 | 213.19K | 7.20K | 3.50% |
Dec 31, 2018 | 205.99K | 22.93K | 12.53% |
Dec 31, 2017 | 183.06K | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
LENSAR | 42.16M |
iCAD, Inc. | 17.32M |
electroCore | 16.03M |
Co-Diagnostics | 6.81M |
Evogene | 5.64M |
IGC Pharma | 1.22M |
VYNE Therapeutics | 424.00K |
MRKR News
- 23 days ago - Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies - GlobeNewsWire
- 5 weeks ago - Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results - GlobeNewsWire
- 5 weeks ago - Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference - GlobeNewsWire
- 3 months ago - Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601 - GlobeNewsWire
- 4 months ago - Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization - GlobeNewsWire
- 4 months ago - Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024” - GlobeNewsWire
- 6 months ago - Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates - GlobeNewsWire
- 8 months ago - Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse - GlobeNewsWire